CMV: current management and opportunities for future treatments for Cytomegalovirus
hemato-oncology, Syndicated Studies, CMV, Infectiology
New in 2023 !
Posts about
Syndicated Studies
MDS: Treatment paradigms are changing
hemato-oncology, Tracking Studies, Syndicated Studies, Oncology
MyeloDysplastic Syndromes: our syndicated research will tell you why - and how - treatment...
Our brand new 2020 Syndicated Surveys
Our range of syndicated studies now covers over 30 indications, many of them with results already...
COVID-19 2nd Phase - Impact on Physicians’ Practice - Syndicated Study
How does COVID-19 affectthe HCPS relationships with patients and with the pharmaceutical industry?...
mRCC: promising new combinations lead to disruption in L1 and L2
Targeted therapies, particularly tyrosine kinase inhibitors (TKI) dominate the treatment of...
COVID-19 road to recovery: 5 key insights from our syndicated study
As the global number of infected cases surpasses 46 million (Nov 2, 2020), there is a non-stop...
DLBCL Patient Insights in the US and EU5
hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies
When working on a new or existing brand within the DLBCL market it's important to have up to date...
DLBCL Treatment Performance in EU5 and US
hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies
The DLBCL market is undergoing a period of change, and the relative performance of the various...
DLBCL Market Overview
hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies, Oncology
Following the release of our latest ebook, this is the first blog post in this series focusing on...
New AplusA eBook Covers the DLBCL Market
AplusA News, hemato-oncology, Tracking Studies, DLBCL market, Syndicated Studies, Oncology
Introducing the latest eBook in AplusA's Hemato-Oncology series